Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study
Won-Seog Kim(Samsung Medical Center), Kensei Tobinai(National Cancer Center), Yok‐Lam Kwong(Queen Mary Hospital), Kazuhito Yamamoto(Aichi Cancer Center), Youko Suehiro(National Hospital Organization Kyushu Cancer Center), Eiju Negoro(University of Fukui Hospital), Koji Izutsu(Tokyo National Hospital), Po‐Shen Ko(Taipei Veterans General Hospital), Hwei‐Fang Tien(Far Eastern Memorial Hospital), Hideaki Nakajima(Yokohama City University Hospital), Noriko Fukuhara(Tohoku University Hospital), Toshiki Uchida(Red Cross Hospital), Fumiko Nagahama, Yusuke Sonehara, Hirokazu Nagai(Tokai University), Kiyoshi Ando(Hiroshima University), Yasuhito Terui(Saitama Medical University Hospital), Dok-Hyun Yoon(Ulsan College), Hye Jin Kang(University of North Carolina at Chapel Hill)
Cited by 10
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
Peripheral T-cell lymphoma, not otherwise specified: a report of 340 cases from the International Peripheral T-cell Lymphoma Project
|Blood|2011|431
Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma
|New England Journal of Medicine|2022|342